---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-357120"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2026-08-19T21:07:17+00:00"
generated_at: "2026-08-19T21:08:18.365565+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences grants CEO and CFO restricted stock with market-cap vesting

## Summary
- CEO James Rolke granted 208,076 restricted shares; CFO Chester Zygmont granted 208,073 shares, effective Aug 17, 2026.
- Awards vest in four 25% tranches upon 20-day market caps of $30M, $60M, $90M, $120M, or by 2nd/4th anniversaries.
- Full vesting on change in control; accelerated on death, termination without cause, or for good reason.
- Unvested shares forfeited on termination for cause, disability, or retirement; dividends held with same restrictions.
- Grants made under Amended and Restated 2021 Equity Incentive Plan; form of award agreement filed as Exhibit 10.1.

## SEC filing metadata
- accession: 0001193125-26-357120
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2026-08-19T21:07:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/0001193125-26-357120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-357120
- JSON: https://secwatch.observer/filing/0001193125-26-357120.json
- Plain text: https://secwatch.observer/filing/0001193125-26-357120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.